Live

fibroblast immunology

1 articles

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

GlobeNewswire Inc.

GlobeNewswire Inc.·Mar 17·Mestag Therapeutics

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.

JNJclinical trialbispecific antibody